NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

NovoCure LimitedNASDAQ: NVCR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $135.13M rose 16.0% year over year, ahead of the +5.7% change in trailing-twelve-month gross profit. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Gross profit amounted to 74.5% of revenue in FY2025, down 2.8 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.0% holds above the trailing-twelve-month pace of +5.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$135.13M+2.2% QoQ
Last fiscal yearDec 2025
$488.47M+4.4% YoY
LTMMar 2026
$507.13M+5.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.0%——
1 year+4.4%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
488.47M USD
Year-over-year change
+4.4%
4-year CAGR
+3.8%

Gross Profit vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 gross profit of $507.13M is the highest of the 4 companies compared; the peer median is $77.75M.
  • Its year-over-year change of +5.7% is the 3rd highest of 4, against a peer median of +23.5%.
  • Gross profit amounts to 75.2% of revenue for NVCR, versus a peer median of 78.3%.
NVCR Competitors Peer median
Gross Profit for NVCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$507.13M +5.7%+4.9%75.2%
NPCENeuroPace, Inc.LTM Mar 2026$77.93M +23.5%+33.4%78.3%
DCTHDelcath Systems, Inc.LTM Mar 2026$77.75M +70.1%+230.6%86.0%
PLSEPulse Biosciences, Inc.LTM Jun 2026-$256K +4.1%—21.6%
Peer median (excluding NVCR) $77.75M+23.5%+132.0%78.3%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue535.03M537.84M509.34M605.22M655.35M
Cost of Revenue114.88M114.87M128.28M137.18M166.88M
Gross Profit420.15M422.97M381.06M468.04M488.47M
Gross Margin78.5%78.6%74.8%77.3%74.5%
Research & Development201.3M206.09M223.06M209.65M224.54M
Selling, General & Admin263.18M306.41M390.87M428.89M417.73M
Operating Expenses464.49M512.5M614.67M638.54M642.27M
Depreciation & Amortization10.25M10.62M10.97M11.24M17.2M
EBITDA(38.38M)(67.89M)(177.45M)(109.58M)(119.05M)
EBITDA Margin-7.2%-12.6%-34.8%-18.1%-18.2%
Operating Income(44.33M)(89.52M)(232.87M)(170.5M)(153.8M)
Operating Margin-8.3%-16.6%-45.7%-28.2%-23.5%
Interest Income1.1M15.79M46.04M51M18.11M
Interest Expense8.84M8.11M4.91M11.66M0
Other Income / Expenses(7.74M)7.68M41.13M39.33M17.55M
Income Before Tax(52.08M)(81.85M)(191.74M)(131.16M)(136.25M)
Pre-Tax Margin-9.7%-15.2%-37.6%-21.7%-20.8%
Income Tax Expense6.28M10.69M15.3M37.47M(23K)
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Net Margin-10.9%-17.2%-40.6%-27.9%-20.8%
EPS (Basic)(0.56)(0.88)(1.95)(1.56)(1.22)
EPS (Diluted)(0.56)(0.88)(1.95)(1.56)(1.22)
Weighted Avg Shares103.43M104.66M106.39M107.83M111.47M
Weighted Avg Shares (Diluted)103.43M104.66M106.39M107.83M111.47M

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.